In a recent study, women who experienced intimate partner violence early in the COVID-19 pandemic reported worse mental health symptoms and modifiable health factors.
Intimate partner violence (IPV) at the start of the COVID-19 pandemic was linked to adverse mental health symptoms and modifiable health factors in women, according to a recent study.
Physical, sexual, or psychological harm from a former or current partner is known as IPV and is experienced by about one-third of women in a relationship. Concerns arose at the start of the COVID-19 pandemic that mitigation efforts such as stay at home orders would isolate individuals in abusive relationships and increase the rate and severity of violence.
The severity of external stressors worsened from the COVID-19 pandemic may be associated with increased risk of IPV exposure, with a worldwide increase of IPV recorded in 2020. Outcomes such as depression and cardiometabolic diseases have been associated with IPV outside of the pandemic, but it is unknown how these factors were affected during the pandemic.
To determine the association between IPV and increased risk of adverse health outcomes in women during the COVID-19 pandemic, investigators conducted a cohort study including 3 cohort samples of women aged 21 to 60 years. Participants filled out an online COVID-19 survey, followed by 3 monthly and 3 quarterly administered surveys.
IPV experiences, mental health symptoms, modifiable health factors, covariates, and history of IPV were measured. Two exposures of IPV experience were measured, the first being a report of having a partner since March 1, 2000, and completing a 6-item version of the Relationship Assessment Tool (RAT).
The second exposure measured was a single item assessing fear of partner. Associations between both exposure measures and health outcomes were measured independently.
Domains of mental health measured include depression, anxiety, and posttraumatic stress symptoms (PTSS). A 4-item Patient Health Questionnaire was used to measure current anxiety and depression, while a 6-item Impact of Events Scale was used to measure current PTSS.
Modifiable health factors measured include sleep quality, sleep duration, physical activity, alcohol use, and alcohol or other substance use for stress management during 2020 and 2021. Adjustments were made for sociodemographic factors such as sex, age, race and ethnicity, educational level, active health care status, partnership status, sexual orientation, and depression and anxiety before exposure ascertainment.
There were 13,597 participants included in the final analysis, aged an average 44 years. Of these, 96.3% were non-Hispanic White, and 92.8% heterosexual. RAT score was associated with a fear of partner, with more participants in the highest RAT score quartile displaying a fear of partner.
An association was found between IPV experiences and depression, anxiety, and PTSS. An IPV experience at 1 month was linked to increased risk of poor mental health outcomes during follow-up. Fear of one’s partner was also associated with worse mental health outcomes during follow-up.
Poorer sleep quality, decreased sleep duration, increased alcohol use, and increased use of alcohol and other substances to manage stress were outcomes associated with IPV experience, with decreased physical activity found in 1 of the 3 cohorts. These outcomes were also associated with fear of one’s partner.
Reference
Scoglio AAJ, Zhu Y, Lawn RB, et al. Intimate partner violence, mental health symptoms, and modifiable health factors in women during the COVID-19 Pandemic in the US. JAMA Netw Open. 2023;6(3):e232977. doi:10.1001/jamanetworkopen.2023.2977
Gender disparity not found for alcohol use disorder’s link to suicide
March 18th 2024A recent study sheds light on the significant association between alcohol use disorder and suicide mortality found regardless of sex, emphasizing the importance of addressing alcohol use disorder in suicide prevention strategies.
Read More
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
NIH: Intervention mitigates postpartum depression and anxiety risks
March 15th 2024A recent study from the National Institutes of Health reveals an intervention led by non-specialist providers during pregnancy significantly lowers postpartum depression and anxiety risks, especially crucial for women in resource-poor settings where mental health care access is limited.
Read More
Surge of antidepressant use seen among female adolescents during COVID-19
March 7th 2024A study revealed a significant increase in antidepressant prescriptions among adolescents and young adults during the COVID-19 pandemic, particularly among female adolescents, indicating exacerbation of pre-existing mental health challenges.
Read More
Hormone therapy shows promise in alleviating menopause-linked depression
February 23rd 2024A recent investigation sheds light on the efficacy of hormone therapy in alleviating depressive symptoms associated with menopause, revealing potential benefits for women undergoing natural menopause.
Read More